Diego Enrico

688 total citations
29 papers, 215 citations indexed

About

Diego Enrico is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Diego Enrico has authored 29 papers receiving a total of 215 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Diego Enrico's work include Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Genomics and Diagnostics (5 papers). Diego Enrico is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Cancer Genomics and Diagnostics (5 papers). Diego Enrico collaborates with scholars based in Argentina, Spain and United States. Diego Enrico's co-authors include Matías Chacón, Benjamin Besse, Angélo Paci, Nathalie Chaput, Martín Ángel, Claudio Martín, Mora Amat, Jorge Nadal, Eduardo Huertas and Carlos H. Barrios and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Diego Enrico

24 papers receiving 210 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Diego Enrico Argentina 8 136 64 45 42 29 29 215
Joan Tymon‐Rosario United States 8 103 0.8× 45 0.7× 39 0.9× 67 1.6× 28 1.0× 34 294
Melita Perić Balja Croatia 9 120 0.9× 29 0.5× 23 0.5× 46 1.1× 26 0.9× 30 231
Sylvia V. Alarcon United States 10 120 0.9× 60 0.9× 55 1.2× 175 4.2× 15 0.5× 20 334
Jack Junjie Chan Singapore 7 123 0.9× 46 0.7× 11 0.2× 50 1.2× 17 0.6× 26 189
Vishal Navani Canada 11 205 1.5× 172 2.7× 42 0.9× 87 2.1× 13 0.4× 38 338
Damé Idossa United States 7 107 0.8× 77 1.2× 10 0.2× 52 1.2× 24 0.8× 22 256
Débora S. Bruno United States 12 215 1.6× 128 2.0× 77 1.7× 51 1.2× 21 0.7× 45 352
Rosario Francesco Di Stefano Italy 8 105 0.8× 153 2.4× 14 0.3× 70 1.7× 24 0.8× 25 276
Berta Hernández Spain 10 243 1.8× 77 1.2× 114 2.5× 43 1.0× 11 0.4× 17 352
Arman Hasani Australia 9 83 0.6× 197 3.1× 58 1.3× 32 0.8× 53 1.8× 16 332

Countries citing papers authored by Diego Enrico

Since Specialization
Citations

This map shows the geographic impact of Diego Enrico's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diego Enrico with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diego Enrico more than expected).

Fields of papers citing papers by Diego Enrico

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diego Enrico. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diego Enrico. The network helps show where Diego Enrico may publish in the future.

Co-authorship network of co-authors of Diego Enrico

This figure shows the co-authorship network connecting the top 25 collaborators of Diego Enrico. A scholar is included among the top collaborators of Diego Enrico based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diego Enrico. Diego Enrico is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Nadal, Jorge, et al.. (2024). The Emerging Role of Tertiary Lymphoid Structures in Breast Cancer: A Narrative Review. Cancers. 16(2). 396–396. 9 indexed citations
3.
Enrico, Diego, et al.. (2024). Higher risk of recurrence in early-stage breast cancer patients with increased levels of ribosomal protein S6. Scientific Reports. 14(1). 25136–25136. 1 indexed citations
4.
Aguirre, Elena, Diego Enrico, Diego Kaen, et al.. (2023). P2.18-04 Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso). Journal of Thoracic Oncology. 18(11). S382–S382. 1 indexed citations
5.
Loria, Fernando Sánchez, et al.. (2023). Short-course radiotherapy for rectal cancer: real-world evidence in Argentina. ecancermedicalscience. 17. 1555–1555. 1 indexed citations
6.
Arrieta, Óscar, Andrés F. Cardona, Vladmir Cláudio Cordeiro de Lima, et al.. (2023). P2.10-13 Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice. Journal of Thoracic Oncology. 18(11). S357–S358.
7.
Enrico, Diego, et al.. (2023). Generalized Lymphatic Anomaly as a Differential Diagnosis of Lytic Lesions. SHILAP Revista de lepidopterología. 16(1). 597–603.
8.
Enrico, Diego, Andrés Rodríguez, Luisina Bruno, et al.. (2023). Atypical pattern of response in rectal cancer after neoadjuvant pembrolizumab treatment: a case report, literature review, and proposed management model. Journal of Gastrointestinal Oncology. 14(3). 1635–1642. 2 indexed citations
9.
Enrico, Diego, et al.. (2023). Breaking the unvirtuous cycle: barriers and opportunities for research and development in Paraguay. A case study. Frontiers in Medicine. 10. 1266246–1266246. 2 indexed citations
10.
Enrico, Diego, et al.. (2022). Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report. JTO Clinical and Research Reports. 4(2). 100456–100456. 9 indexed citations
11.
López, Carlos, et al.. (2022). Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: A systematic review. Critical Reviews in Oncology/Hematology. 176. 103747–103747. 6 indexed citations
12.
Martín, Claudio & Diego Enrico. (2022). Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. Frontiers in Oncology. 12. 962947–962947. 6 indexed citations
13.
O’Connor, Juan Manuel, Eduardo Huertas, Fernando Sánchez Loria, et al.. (2022). Implementation of a virtual multicenter gastrointestinal tumor board to reduce cancer disparities in Argentina. World Journal of Clinical Oncology. 13(6). 423–428. 8 indexed citations
14.
Ángel, Martín, et al.. (2022). Desmoid tumour in an inguinal hernia in a patient with a previous diagnosis of melanoma. ecancermedicalscience. 16. 1394–1394.
15.
Enrico, Diego, et al.. (2021). Analysis of adverse events attribution and reporting in cancer clinical trials: A systematic review. Critical Reviews in Oncology/Hematology. 160. 103296–103296. 6 indexed citations
16.
Ángel, Martín, Renata Colombo Bonadio, Guilherme Harada, et al.. (2020). Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project). ESMO Open. 5(6). e000988–e000988. 7 indexed citations
17.
Enrico, Diego, Christophe Massard, & Benjamin Besse. (2019). Exploring the optimal use of alectinib. The Lancet Respiratory Medicine. 7(5). 373–374. 2 indexed citations
18.
Enrico, Diego, Ludovic Lacroix, Étienne Rouleau, et al.. (2019). Multiple synchronous mechanisms may contribute to osimertinib resistance in non-small cell lung cancer (NSCLC) patients: Insights of the MATCH-R study. Annals of Oncology. 30. v627–v627. 5 indexed citations
19.
Batagelj, Emilio, et al.. (2018). Analysis of EML4-ALK rearrangement in non-small cell lung cancer in Argentina. Annals of Diagnostic Pathology. 34. 77–81. 5 indexed citations
20.
Acevedo, Roberto, et al.. (2016). Hepatic Resection for Breast Cancer Liver Metastases. 1(2). 1–7.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joan Tymon‐Rosario Breakdown of academic impact, for papers by Melita Perić Balja Breakdown of academic impact, for papers by Sylvia V. Alarcon Breakdown of academic impact, for papers by Jack Junjie Chan Breakdown of academic impact, for papers by Vishal Navani Breakdown of academic impact, for papers by Damé Idossa Breakdown of academic impact, for papers by Débora S. Bruno Breakdown of academic impact, for papers by Rosario Francesco Di Stefano Breakdown of academic impact, for papers by Berta Hernández Breakdown of academic impact, for papers by Arman Hasani
Rankless by CCL
2026